Last updated: February 21, 2026
What is NDC 83745-0232?
NDC 83745-0232 refers to a specific drug listed in the National Drug Code (NDC) database. As of current data, this NDC corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb for cancer immunotherapy. This drug is approved for use in multiple indications, including metastatic non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma.
Market Size and Growth Dynamics
Current Market Scope
- The global immuno-oncology market was valued at $13.1 billion in 2022.
- Nivolumab accounts for approximately 35-40% of this market.
- Estimated U.S. sales for Nivolumab reached $4.6 billion in 2022.
Key Competitive Landscape
- Other PD-1/PD-L1 inhibitors: Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Durvalumab (Imfinzi).
- Nivolumab's market share in immuno-oncology remains competitive, with penetration in lung, melanoma, and kidney cancers.
Market Drivers
- Increase in lung, melanoma, and renal cancers.
- Growing approval in combination regimens.
- Expanded indications, including Hodgkin lymphoma and microsatellite instability-high (MSI-H) tumors.
Market Challenges
- Patent expirations affecting pricing.
- Competition from biosimilars and new molecules.
- Cost of therapy impacting adoption rates.
Price History and Trends
Current Pricing (2010-2023)
| Year |
Approximate Cost per 240 mg Nivolumab Vial |
Notes |
| 2010 |
Not available |
Drug not yet approved |
| 2015 |
$5,000 |
Early adoption phase |
| 2018 |
$6,500 |
Market maturity, stable prices |
| 2021 |
$7,200 |
Slight increase, inflation adjustment |
| 2023 |
$7,500 |
Post-patent expiry considerations, competitive pricing pressures |
Pricing Comparison
- Nivolumab's current list price exceeds that of Pembrolizumab, which averages $7,800 for a 200 mg dose.
- Marketing strategies and reimbursement negotiations influence net prices.
Reimbursement Trends
- Medicaid and Medicare negotiate discounts, with net prices typically 10-20% lower.
- Payer pressure and biosimilar threats may push prices downward.
Price Projection (2023-2028)
Assumptions
- Continued expansion of indications.
- Moderate price erosion due to biosimilar entry and competitive pressures.
- Annual volume growth of 4-6% driven by increased adoption.
Forecast Summary
| Year |
Projected Price per 240 mg Vial |
Change from Prior Year |
Volume Growth |
Total Revenue Estimate |
| 2024 |
$7,300 |
-2.7% |
5% |
~$4.95 billion |
| 2025 |
$7,050 |
-3.4% |
5% |
~$4.8 billion |
| 2026 |
$6,800 |
-3.5% |
6% |
~$5.45 billion |
| 2027 |
$6,600 |
-2.9% |
6% |
~$5.9 billion |
| 2028 |
$6,400 |
-3.0% |
6% |
~$6.4 billion |
Key Factors Impacting Pricing
- Biosimilar development and approval could reduce prices by 10-20% over five years.
- Increasing use in combination therapies may stabilize or slightly increase overall revenues despite price erosion.
- Regulatory and policy changes targeting drug prices.
Geographical Market Variance
- United States: Highest price stability with significant reimbursement coverage.
- Europe: Competitive pricing due to national negotiations.
- Emerging markets: Lower prices driven by affordability and local regulation.
Regulatory and Policy Impacts
- Price controls in certain jurisdictions may cap maximum allowable prices.
- Value-based pricing models could influence future list prices.
Strategic Considerations for Stakeholders
- Manufacturers should prepare for patent cliff effects by optimizing manufacturing efficiency.
- Payers will exert more pressure to reduce net costs, favoring value-based agreements.
- R&D should focus on combination therapies and novel indications to sustain growth.
Key Takeaways
- NDC 83745-0232 (Nivolumab) commands premium pricing, with stable revenues driven by expanding indications.
- Market growth persists despite competitive pressures and biosimilar threats; volume increases compensate for price erosion.
- Price projections forecast modest declines but overall revenue growth due to increased adoption.
- Pricing strategies will remain sensitive to regulatory policies and biosimilar entry.
Frequently Asked Questions
1. How will biosimilar competition affect Nivolumab’s price?
Biosimilar approval could lead to a 10-20% reduction in list prices over five years, depending on market penetration.
2. Are there emerging indications that could impact sales?
Yes, approvals for Hodgkin lymphoma and MSI-H tumors expand the market, potentially offsetting price declines through volume growth.
3. What is the impact of healthcare policies on Nivolumab pricing?
Policy changes, especially those favoring value-based pricing or price caps, will likely pressure net prices.
4. How do reimbursement strategies influence net revenue?
Negotiated discounts, rebates, and coverage policies significantly reduce actual transaction prices from list prices.
5. Will emerging combination therapies alter the market landscape?
Combination regimens can increase overall use, maintaining revenue streams despite price pressure.
Citations
[1] GlobalData. (2022). Immuno-oncology market analysis.
[2] IQVIA. (2023). U.S. Oncology Trend Report.
[3] FDA. (2022). Nivolumab approval expansions.
[4] EvaluatePharma. (2022). Oncology drug pricing analysis.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies.
